PTGS2 and esophageal cancer: In the clinical setting, high rates of transforming growth factor (TGF)-β1, vascular endothelial growth factor (VEGF), and Cox2 expression have been found to be associated with poor prognosis in patients with esophageal cancer [27]–[30].